Reduction of Vasogenic Edema and Infarction by MK-801 in Rats after Temporary Focal Cerebral Ischemia

    loading  Checking for direct PDF access through Ovid

Abstract

ABSTRACT

BLOOD-BRAIN BARRIER PERMEABILITY alteration, vasogenic brain edema, and infarction, which are more extensive after 3 hours of temporary middle cerebral artery occlusion (MCAO) and 3 hours of reperfusion than after 6 hours of permanent MCAO, develop in rats after prolonged focal cerebral ischemia. Protective effects of excitatory amino acid receptor antagonists have been previously demonstrated after temporary global ischemia and permanent focal ischemia in rats. The purpose of this study was to evaluate the effectiveness of MK-801, a noncompetitive N-methyl-D-aspartate receptor antagonist, in temporary middle cerebral artery occlusion in rats maintained at physiological levels of brain temperature. Rats were anesthetized with chloral hydrate (350 mg/kg, intraperitoneally). The MCAO of rats was occluded by cannulation with a nylon suture for 3 hours, followed by 3 hours of reperfusion accomplished by withdrawing the suture. MK-801 (1 mg/kg, intravenously) or saline (S) was injected immediately before the onset of MCAO. Water content (MK-801, n = 6; S, n = 6), Evans blue dye extravasation (MK-801, n = 6; S, n = 6), infarct volume (MK-801, n = 10; S, n = 10), histology (MK-801, n = 6; S, n = 6), and neurological deficit (MK-801, n = 15; S, n = 18) were measured at the end of 3 hours of reperfusion. Brain temperature was monitored during the experiment. The infarction area (measured by 2, 3, 5-triphenyltetrazolium chloride staining) was reduced (P < 0.001) in the MK-801-treated rats, as was the infarct volume and the severity of neuronal damage (P < 0.01). The water content of the cerebral cortex and the blood-brain barrier permeability to Evans blue in both the cerebral cortex and the basal ganglia as well as the neurological deficit grades were significantly reduced in the MK-801 treated group (P < 0.05). These results demonstrate that the noncompetitive N-methyl-D-aspartate receptor antagonist, MK-801, given immediately before 3 hours of temporary MCAO, significantly decreased infarction volume, attenuated ischemic vasogenic brain edema, and improved neurological function in the absence of hypothermia.

Related Topics

    loading  Loading Related Articles